0
ERRATUM
Erratum
Psychiatric News
Volume 41 Number 21 page 30-30

In the article “Companies Desperately Seek Antidepressant Breakthrough” in the June 2 issue, the investigational antidepressant medication desvenlafaxine was incorrectly said to be under development by GlaxoSmithKline (GSk). The drug is actually under development by Wyeth, which also developed and markets venlafaxine (Effexor), the parent compound of desvenlafaxine. A chart accompanying the article correctly listed Wyeth as the developer. ▪

Interactive Graphics

Video

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).
Related Articles
Articles